PHARMACYTE BIOTECH, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
PHARMACYTE BIOTECH, INC. (PMCB) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$19.42 million for the 12-month period ending 2026-04-30, per its 10-K filed 2026-07-29.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-07-29
- PHARMACYTE BIOTECH, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2026 was -$19.42M, a 163.36% decline from fiscal 2025.
- PHARMACYTE BIOTECH, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $30.66M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2026-04-30 | -$19.42M 10-K · filed 2026-07-29 |
| 2025-04-30 | $30.66M 10-K · filed 2026-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |